Global Injectable HIV Treatment Market Growth 2026-2032
The global Injectable HIV Treatment market size is predicted to grow from US$ 296 million in 2025 to US$ 827 million in 2032; it is expected to grow at a CAGR of 15.8% from 2026 to 2032.
Injectable HIV treatment refers to antiretroviral therapy (ART) strategies and drug products administered by injection?most commonly intramuscular or subcutaneous?to deliver one or more antiviral active ingredients in immediate-release or, more typically, depot/extended-release forms that maintain therapeutic exposure over a defined interval to continuously suppress viral replication. The approach is intended to address real-world limitations of daily oral ART, where long-term outcomes can be constrained not by pharmacologic potency but by adherence variability, treatment fatigue, privacy and stigma pressures, regimen complexity in patients with comorbidities, and individual differences in oral absorption and gastrointestinal tolerability; by reducing dosing frequency and converting medication-taking into scheduled care encounters, injectable treatment can improve persistence and quality of life when supported by reliable follow-up systems. Historically, HIV care began with predominantly oral combination regimens and progressed through successive generations of safer, more potent, and higher?resistance-barrier agents; as efficacy became more consistent, innovation increasingly focused on delivery and durability in real-world settings, with injectable therapy evolving from shorter-acting parenteral use in specific clinical situations to long-acting maintenance treatment enabled by advances in formulation science, controlled-release delivery platforms, and aseptic manufacturing. The upstream supply chain typically includes APIs and key intermediates (specialty chemicals, chiral reagents, solvents, catalysts), injection-grade excipients and delivery materials (buffers, tonicity agents, stabilizers, surfactants, solubilizers, and for long-acting depots, polymer or lipid carriers), sterile disposables and packaging (prefilled syringes, needles and safety devices, glass vials or high-barrier containers, rubber stoppers and seals, sterile filtration membranes, single-use tubing and aseptic connectors), and critical manufacturing/QC ?components? (metering pumps and valve assemblies for aseptic filling lines, isolator/laminar-flow filtration elements, in-line pressure/flow/temperature sensors, fill-volume and visible-particle inspection modules, and cold-chain monitoring devices). Because injectable treatment imposes stringent requirements for sterility assurance, particulate/visible matter control, extractables and leachables, release-profile consistency, and storage stability, pharmaceutical-grade material quality systems and supply robustness upstream are often decisive for scalable commercialization and batch-to-batch consistency.In 2025, global production capacity for injectable HIV treatment reached 150,000 doses, while sales amounted to 129,500 doses. The average selling price was approximately USD 2,335 per dose, and gross margins across manufacturers were in the range of 60%?70%.
In the current market, injectable HIV treatment is moving from being perceived as a novel modality to a more clearly stratified option, and discussions among clinicians and payers are increasingly centered on real-world management. In practice, injectable regimens are often positioned for people with higher adherence risk, those who struggle to sustain daily oral therapy, or those seeking to reduce the visibility of daily dosing, with particular emphasis on maintenance after stable suppression and continuity under structured follow-up. Commercial execution is tightly coupled to operational readiness: standardized eligibility and screening, predictable appointment cadence, clinic administration capacity, cold-chain and inventory turnover, and coordinated management of adverse events across care teams. As real-world experience grows, decision-making is shifting from efficacy confirmation to pragmatic questions?how to prevent missed visits, how to switch safely, and how to maintain continuity during relocation or changing providers?so injectable treatment increasingly behaves like an ongoing service pathway rather than a one-time prescription.
Looking ahead, the direction of travel points to lower friction, greater system resilience, and more durable long-term management, driven by formulation advances, regimen optimization, and delivery-model innovation in parallel. Formulation work will focus on improving local tolerability, reducing injection burden, and strengthening storage and transport stability to lessen dependence on strict cold-chain logistics and highly specialized administration. Regimen strategy will increasingly prioritize high resistance barriers and smoother switching, with more disciplined, protocolized mitigation for delays or missed visits, including structured use of oral ?bridging? or contingency approaches where appropriate. Care delivery is also expected to become more decentralized, extending administration beyond large hospitals to community clinics, specialty practices, partnered pharmacy sites, or mobile teams, while layering telehealth follow-up, digital scheduling and reminders, and patient navigation services to reduce time costs and improve predictability. In parallel, guidelines and regulatory expectations are likely to become more granular around screening, monitoring, switching, and interruption management, providing a more standardized operating framework for scale-up.
Drivers and barriers will continue to coexist. Momentum comes from public health priorities to reduce interruptions and onward transmission, patient demand for quality of life and discretion, and clinical urgency to improve real-world adherence and retention; payers also tend to focus on avoiding downstream burden associated with lapses in suppression. Constraints are concentrated in delivery and risk management: reliance on healthcare facilities creates geographic access disparities; appointment logistics and cold-chain/inventory management can strain lower-resourced sites; injection-site reactions and long-term tolerability require training and standardization; and delayed dosing or interruption can create vulnerability during a pharmacokinetic ?tail,? raising resistance and transmission concerns unless follow-up and contingency protocols are tightly executed. Social factors?stigma, privacy concerns, needle aversion, and the inconvenience of repeated clinic visits?can further reduce persistence, while limited testing capacity, follow-up infrastructure, and supply reliability can be binding constraints in resource-constrained settings. As a result, competitive advantage will increasingly hinge not only on the drug and formulation, but on delivering a low-friction, scalable end-to-end pathway across screening, administration, follow-up, supply assurance, and risk mitigation.
LP Information, Inc. (LPI) ' newest research report, the ?Injectable HIV Treatment Industry Forecast? looks at past sales and reviews total world Injectable HIV Treatment sales in 2025, providing a comprehensive analysis by region and market sector of projected Injectable HIV Treatment sales for 2026 through 2032. With Injectable HIV Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Injectable HIV Treatment industry.
This Insight Report provides a comprehensive analysis of the global Injectable HIV Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Injectable HIV Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Injectable HIV Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Injectable HIV Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Injectable HIV Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Injectable HIV Treatment market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Injectable HIV treatment refers to antiretroviral therapy (ART) strategies and drug products administered by injection?most commonly intramuscular or subcutaneous?to deliver one or more antiviral active ingredients in immediate-release or, more typically, depot/extended-release forms that maintain therapeutic exposure over a defined interval to continuously suppress viral replication. The approach is intended to address real-world limitations of daily oral ART, where long-term outcomes can be constrained not by pharmacologic potency but by adherence variability, treatment fatigue, privacy and stigma pressures, regimen complexity in patients with comorbidities, and individual differences in oral absorption and gastrointestinal tolerability; by reducing dosing frequency and converting medication-taking into scheduled care encounters, injectable treatment can improve persistence and quality of life when supported by reliable follow-up systems. Historically, HIV care began with predominantly oral combination regimens and progressed through successive generations of safer, more potent, and higher?resistance-barrier agents; as efficacy became more consistent, innovation increasingly focused on delivery and durability in real-world settings, with injectable therapy evolving from shorter-acting parenteral use in specific clinical situations to long-acting maintenance treatment enabled by advances in formulation science, controlled-release delivery platforms, and aseptic manufacturing. The upstream supply chain typically includes APIs and key intermediates (specialty chemicals, chiral reagents, solvents, catalysts), injection-grade excipients and delivery materials (buffers, tonicity agents, stabilizers, surfactants, solubilizers, and for long-acting depots, polymer or lipid carriers), sterile disposables and packaging (prefilled syringes, needles and safety devices, glass vials or high-barrier containers, rubber stoppers and seals, sterile filtration membranes, single-use tubing and aseptic connectors), and critical manufacturing/QC ?components? (metering pumps and valve assemblies for aseptic filling lines, isolator/laminar-flow filtration elements, in-line pressure/flow/temperature sensors, fill-volume and visible-particle inspection modules, and cold-chain monitoring devices). Because injectable treatment imposes stringent requirements for sterility assurance, particulate/visible matter control, extractables and leachables, release-profile consistency, and storage stability, pharmaceutical-grade material quality systems and supply robustness upstream are often decisive for scalable commercialization and batch-to-batch consistency.In 2025, global production capacity for injectable HIV treatment reached 150,000 doses, while sales amounted to 129,500 doses. The average selling price was approximately USD 2,335 per dose, and gross margins across manufacturers were in the range of 60%?70%.
In the current market, injectable HIV treatment is moving from being perceived as a novel modality to a more clearly stratified option, and discussions among clinicians and payers are increasingly centered on real-world management. In practice, injectable regimens are often positioned for people with higher adherence risk, those who struggle to sustain daily oral therapy, or those seeking to reduce the visibility of daily dosing, with particular emphasis on maintenance after stable suppression and continuity under structured follow-up. Commercial execution is tightly coupled to operational readiness: standardized eligibility and screening, predictable appointment cadence, clinic administration capacity, cold-chain and inventory turnover, and coordinated management of adverse events across care teams. As real-world experience grows, decision-making is shifting from efficacy confirmation to pragmatic questions?how to prevent missed visits, how to switch safely, and how to maintain continuity during relocation or changing providers?so injectable treatment increasingly behaves like an ongoing service pathway rather than a one-time prescription.
Looking ahead, the direction of travel points to lower friction, greater system resilience, and more durable long-term management, driven by formulation advances, regimen optimization, and delivery-model innovation in parallel. Formulation work will focus on improving local tolerability, reducing injection burden, and strengthening storage and transport stability to lessen dependence on strict cold-chain logistics and highly specialized administration. Regimen strategy will increasingly prioritize high resistance barriers and smoother switching, with more disciplined, protocolized mitigation for delays or missed visits, including structured use of oral ?bridging? or contingency approaches where appropriate. Care delivery is also expected to become more decentralized, extending administration beyond large hospitals to community clinics, specialty practices, partnered pharmacy sites, or mobile teams, while layering telehealth follow-up, digital scheduling and reminders, and patient navigation services to reduce time costs and improve predictability. In parallel, guidelines and regulatory expectations are likely to become more granular around screening, monitoring, switching, and interruption management, providing a more standardized operating framework for scale-up.
Drivers and barriers will continue to coexist. Momentum comes from public health priorities to reduce interruptions and onward transmission, patient demand for quality of life and discretion, and clinical urgency to improve real-world adherence and retention; payers also tend to focus on avoiding downstream burden associated with lapses in suppression. Constraints are concentrated in delivery and risk management: reliance on healthcare facilities creates geographic access disparities; appointment logistics and cold-chain/inventory management can strain lower-resourced sites; injection-site reactions and long-term tolerability require training and standardization; and delayed dosing or interruption can create vulnerability during a pharmacokinetic ?tail,? raising resistance and transmission concerns unless follow-up and contingency protocols are tightly executed. Social factors?stigma, privacy concerns, needle aversion, and the inconvenience of repeated clinic visits?can further reduce persistence, while limited testing capacity, follow-up infrastructure, and supply reliability can be binding constraints in resource-constrained settings. As a result, competitive advantage will increasingly hinge not only on the drug and formulation, but on delivering a low-friction, scalable end-to-end pathway across screening, administration, follow-up, supply assurance, and risk mitigation.
LP Information, Inc. (LPI) ' newest research report, the ?Injectable HIV Treatment Industry Forecast? looks at past sales and reviews total world Injectable HIV Treatment sales in 2025, providing a comprehensive analysis by region and market sector of projected Injectable HIV Treatment sales for 2026 through 2032. With Injectable HIV Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Injectable HIV Treatment industry.
This Insight Report provides a comprehensive analysis of the global Injectable HIV Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Injectable HIV Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Injectable HIV Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Injectable HIV Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Injectable HIV Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Injectable HIV Treatment market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Cabotegravir
- Rilpivirine
- Lenacapavir
- Ibalizumab
- Other
- Short-interval Injections
- Monthly Injections
- Quarterly Injections
- Original Drug
- Generic Drug
- Pre-Exposure Prophylaxis
- HIV Treatment
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- ViiV Healthcare
- Janssen Pharmaceuticals
- Gilead Sciences
- Theratechnologies
- What is the 10-year outlook for the global Injectable HIV Treatment market?
- What factors are driving Injectable HIV Treatment market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How doInjectable HIV Treatment market opportunities vary by end market size?
- How does Injectable HIV Treatment break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Injectable HIV Treatment Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Injectable HIV Treatment by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Injectable HIV Treatment by Country/Region, 2021, 2025 & 2032
2.2 Injectable HIV Treatment Segment by Type
2.2.1 Cabotegravir
2.2.2 Rilpivirine
2.2.3 Lenacapavir
2.2.4 Ibalizumab
2.2.5 Other
2.2.6 Injectable HIV Treatment Sales by Type
2.2.6.1 Global Injectable HIV Treatment Sales Market Share by Type (2021-2026)
2.2.6.2 Global Injectable HIV Treatment Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global Injectable HIV Treatment Sale Price by Type (2021-2026)
2.3 Injectable HIV Treatment Segment by Application
2.3.1 Pre-Exposure Prophylaxis
2.3.2 HIV Treatment
2.3.3 Injectable HIV Treatment Sales by Application
2.3.3.1 Global Injectable HIV Treatment Sale Market Share by Application (2021-2026)
2.3.3.2 Global Injectable HIV Treatment Revenue and Market Share by Application (2021-2026)
2.3.3.3 Global Injectable HIV Treatment Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Injectable HIV Treatment Breakdown Data by Company
3.1.1 Global Injectable HIV Treatment Annual Sales by Company (2021-2026)
3.1.2 Global Injectable HIV Treatment Sales Market Share by Company (2021-2026)
3.2 Global Injectable HIV Treatment Annual Revenue by Company (2021-2026)
3.2.1 Global Injectable HIV Treatment Revenue by Company (2021-2026)
3.2.2 Global Injectable HIV Treatment Revenue Market Share by Company (2021-2026)
3.3 Global Injectable HIV Treatment Sale Price by Company
3.4 Key Manufacturers Injectable HIV Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Injectable HIV Treatment Product Location Distribution
3.4.2 Players Injectable HIV Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR INJECTABLE HIV TREATMENT BY GEOGRAPHIC REGION
4.1 World Historic Injectable HIV Treatment Market Size by Geographic Region (2021-2026)
4.1.1 Global Injectable HIV Treatment Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Injectable HIV Treatment Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Injectable HIV Treatment Market Size by Country/Region (2021-2026)
4.2.1 Global Injectable HIV Treatment Annual Sales by Country/Region (2021-2026)
4.2.2 Global Injectable HIV Treatment Annual Revenue by Country/Region (2021-2026)
4.3 Americas Injectable HIV Treatment Sales Growth
4.4 APAC Injectable HIV Treatment Sales Growth
4.5 Europe Injectable HIV Treatment Sales Growth
4.6 Middle East & Africa Injectable HIV Treatment Sales Growth
5 AMERICAS
5.1 Americas Injectable HIV Treatment Sales by Country
5.1.1 Americas Injectable HIV Treatment Sales by Country (2021-2026)
5.1.2 Americas Injectable HIV Treatment Revenue by Country (2021-2026)
5.2 Americas Injectable HIV Treatment Sales by Type (2021-2026)
5.3 Americas Injectable HIV Treatment Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Injectable HIV Treatment Sales by Region
6.1.1 APAC Injectable HIV Treatment Sales by Region (2021-2026)
6.1.2 APAC Injectable HIV Treatment Revenue by Region (2021-2026)
6.2 APAC Injectable HIV Treatment Sales by Type (2021-2026)
6.3 APAC Injectable HIV Treatment Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Injectable HIV Treatment by Country
7.1.1 Europe Injectable HIV Treatment Sales by Country (2021-2026)
7.1.2 Europe Injectable HIV Treatment Revenue by Country (2021-2026)
7.2 Europe Injectable HIV Treatment Sales by Type (2021-2026)
7.3 Europe Injectable HIV Treatment Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Injectable HIV Treatment by Country
8.1.1 Middle East & Africa Injectable HIV Treatment Sales by Country (2021-2026)
8.1.2 Middle East & Africa Injectable HIV Treatment Revenue by Country (2021-2026)
8.2 Middle East & Africa Injectable HIV Treatment Sales by Type (2021-2026)
8.3 Middle East & Africa Injectable HIV Treatment Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Injectable HIV Treatment
10.3 Manufacturing Process Analysis of Injectable HIV Treatment
10.4 Industry Chain Structure of Injectable HIV Treatment
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Injectable HIV Treatment Distributors
11.3 Injectable HIV Treatment Customer
12 WORLD FORECAST REVIEW FOR INJECTABLE HIV TREATMENT BY GEOGRAPHIC REGION
12.1 Global Injectable HIV Treatment Market Size Forecast by Region
12.1.1 Global Injectable HIV Treatment Forecast by Region (2027-2032)
12.1.2 Global Injectable HIV Treatment Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Injectable HIV Treatment Forecast by Type (2027-2032)
12.7 Global Injectable HIV Treatment Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 ViiV Healthcare
13.1.1 ViiV Healthcare Company Information
13.1.2 ViiV Healthcare Injectable HIV Treatment Product Portfolios and Specifications
13.1.3 ViiV Healthcare Injectable HIV Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 ViiV Healthcare Main Business Overview
13.1.5 ViiV Healthcare Latest Developments
13.2 Janssen Pharmaceuticals
13.2.1 Janssen Pharmaceuticals Company Information
13.2.2 Janssen Pharmaceuticals Injectable HIV Treatment Product Portfolios and Specifications
13.2.3 Janssen Pharmaceuticals Injectable HIV Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Janssen Pharmaceuticals Main Business Overview
13.2.5 Janssen Pharmaceuticals Latest Developments
13.3 Gilead Sciences
13.3.1 Gilead Sciences Company Information
13.3.2 Gilead Sciences Injectable HIV Treatment Product Portfolios and Specifications
13.3.3 Gilead Sciences Injectable HIV Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Gilead Sciences Main Business Overview
13.3.5 Gilead Sciences Latest Developments
13.4 Theratechnologies
13.4.1 Theratechnologies Company Information
13.4.2 Theratechnologies Injectable HIV Treatment Product Portfolios and Specifications
13.4.3 Theratechnologies Injectable HIV Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Theratechnologies Main Business Overview
13.4.5 Theratechnologies Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Injectable HIV Treatment Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Injectable HIV Treatment by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Injectable HIV Treatment by Country/Region, 2021, 2025 & 2032
2.2 Injectable HIV Treatment Segment by Type
2.2.1 Cabotegravir
2.2.2 Rilpivirine
2.2.3 Lenacapavir
2.2.4 Ibalizumab
2.2.5 Other
2.2.6 Injectable HIV Treatment Sales by Type
2.2.6.1 Global Injectable HIV Treatment Sales Market Share by Type (2021-2026)
2.2.6.2 Global Injectable HIV Treatment Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global Injectable HIV Treatment Sale Price by Type (2021-2026)
2.3 Injectable HIV Treatment Segment by Application
2.3.1 Pre-Exposure Prophylaxis
2.3.2 HIV Treatment
2.3.3 Injectable HIV Treatment Sales by Application
2.3.3.1 Global Injectable HIV Treatment Sale Market Share by Application (2021-2026)
2.3.3.2 Global Injectable HIV Treatment Revenue and Market Share by Application (2021-2026)
2.3.3.3 Global Injectable HIV Treatment Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Injectable HIV Treatment Breakdown Data by Company
3.1.1 Global Injectable HIV Treatment Annual Sales by Company (2021-2026)
3.1.2 Global Injectable HIV Treatment Sales Market Share by Company (2021-2026)
3.2 Global Injectable HIV Treatment Annual Revenue by Company (2021-2026)
3.2.1 Global Injectable HIV Treatment Revenue by Company (2021-2026)
3.2.2 Global Injectable HIV Treatment Revenue Market Share by Company (2021-2026)
3.3 Global Injectable HIV Treatment Sale Price by Company
3.4 Key Manufacturers Injectable HIV Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Injectable HIV Treatment Product Location Distribution
3.4.2 Players Injectable HIV Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR INJECTABLE HIV TREATMENT BY GEOGRAPHIC REGION
4.1 World Historic Injectable HIV Treatment Market Size by Geographic Region (2021-2026)
4.1.1 Global Injectable HIV Treatment Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Injectable HIV Treatment Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Injectable HIV Treatment Market Size by Country/Region (2021-2026)
4.2.1 Global Injectable HIV Treatment Annual Sales by Country/Region (2021-2026)
4.2.2 Global Injectable HIV Treatment Annual Revenue by Country/Region (2021-2026)
4.3 Americas Injectable HIV Treatment Sales Growth
4.4 APAC Injectable HIV Treatment Sales Growth
4.5 Europe Injectable HIV Treatment Sales Growth
4.6 Middle East & Africa Injectable HIV Treatment Sales Growth
5 AMERICAS
5.1 Americas Injectable HIV Treatment Sales by Country
5.1.1 Americas Injectable HIV Treatment Sales by Country (2021-2026)
5.1.2 Americas Injectable HIV Treatment Revenue by Country (2021-2026)
5.2 Americas Injectable HIV Treatment Sales by Type (2021-2026)
5.3 Americas Injectable HIV Treatment Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Injectable HIV Treatment Sales by Region
6.1.1 APAC Injectable HIV Treatment Sales by Region (2021-2026)
6.1.2 APAC Injectable HIV Treatment Revenue by Region (2021-2026)
6.2 APAC Injectable HIV Treatment Sales by Type (2021-2026)
6.3 APAC Injectable HIV Treatment Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Injectable HIV Treatment by Country
7.1.1 Europe Injectable HIV Treatment Sales by Country (2021-2026)
7.1.2 Europe Injectable HIV Treatment Revenue by Country (2021-2026)
7.2 Europe Injectable HIV Treatment Sales by Type (2021-2026)
7.3 Europe Injectable HIV Treatment Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Injectable HIV Treatment by Country
8.1.1 Middle East & Africa Injectable HIV Treatment Sales by Country (2021-2026)
8.1.2 Middle East & Africa Injectable HIV Treatment Revenue by Country (2021-2026)
8.2 Middle East & Africa Injectable HIV Treatment Sales by Type (2021-2026)
8.3 Middle East & Africa Injectable HIV Treatment Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Injectable HIV Treatment
10.3 Manufacturing Process Analysis of Injectable HIV Treatment
10.4 Industry Chain Structure of Injectable HIV Treatment
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Injectable HIV Treatment Distributors
11.3 Injectable HIV Treatment Customer
12 WORLD FORECAST REVIEW FOR INJECTABLE HIV TREATMENT BY GEOGRAPHIC REGION
12.1 Global Injectable HIV Treatment Market Size Forecast by Region
12.1.1 Global Injectable HIV Treatment Forecast by Region (2027-2032)
12.1.2 Global Injectable HIV Treatment Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Injectable HIV Treatment Forecast by Type (2027-2032)
12.7 Global Injectable HIV Treatment Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 ViiV Healthcare
13.1.1 ViiV Healthcare Company Information
13.1.2 ViiV Healthcare Injectable HIV Treatment Product Portfolios and Specifications
13.1.3 ViiV Healthcare Injectable HIV Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 ViiV Healthcare Main Business Overview
13.1.5 ViiV Healthcare Latest Developments
13.2 Janssen Pharmaceuticals
13.2.1 Janssen Pharmaceuticals Company Information
13.2.2 Janssen Pharmaceuticals Injectable HIV Treatment Product Portfolios and Specifications
13.2.3 Janssen Pharmaceuticals Injectable HIV Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Janssen Pharmaceuticals Main Business Overview
13.2.5 Janssen Pharmaceuticals Latest Developments
13.3 Gilead Sciences
13.3.1 Gilead Sciences Company Information
13.3.2 Gilead Sciences Injectable HIV Treatment Product Portfolios and Specifications
13.3.3 Gilead Sciences Injectable HIV Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Gilead Sciences Main Business Overview
13.3.5 Gilead Sciences Latest Developments
13.4 Theratechnologies
13.4.1 Theratechnologies Company Information
13.4.2 Theratechnologies Injectable HIV Treatment Product Portfolios and Specifications
13.4.3 Theratechnologies Injectable HIV Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Theratechnologies Main Business Overview
13.4.5 Theratechnologies Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Injectable HIV Treatment Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Injectable HIV Treatment Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Cabotegravir
Table 4. Major Players of Rilpivirine
Table 5. Major Players of Lenacapavir
Table 6. Major Players of Ibalizumab
Table 7. Major Players of Other
Table 8. Global Injectable HIV Treatment Sales by Type (2021-2026) & (K Units)
Table 9. Global Injectable HIV Treatment Sales Market Share by Type (2021-2026)
Table 10. Global Injectable HIV Treatment Revenue by Type (2021-2026) & ($ million)
Table 11. Global Injectable HIV Treatment Revenue Market Share by Type (2021-2026)
Table 12. Global Injectable HIV Treatment Sale Price by Type (2021-2026) & (US$/Unit)
Table 13. Global Injectable HIV Treatment Sale by Application (2021-2026) & (K Units)
Table 14. Global Injectable HIV Treatment Sale Market Share by Application (2021-2026)
Table 15. Global Injectable HIV Treatment Revenue by Application (2021-2026) & ($ million)
Table 16. Global Injectable HIV Treatment Revenue Market Share by Application (2021-2026)
Table 17. Global Injectable HIV Treatment Sale Price by Application (2021-2026) & (US$/Unit)
Table 18. Global Injectable HIV Treatment Sales by Company (2021-2026) & (K Units)
Table 19. Global Injectable HIV Treatment Sales Market Share by Company (2021-2026)
Table 20. Global Injectable HIV Treatment Revenue by Company (2021-2026) & ($ millions)
Table 21. Global Injectable HIV Treatment Revenue Market Share by Company (2021-2026)
Table 22. Global Injectable HIV Treatment Sale Price by Company (2021-2026) & (US$/Unit)
Table 23. Key Manufacturers Injectable HIV Treatment Producing Area Distribution and Sales Area
Table 24. Players Injectable HIV Treatment Products Offered
Table 25. Injectable HIV Treatment Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Injectable HIV Treatment Sales by Geographic Region (2021-2026) & (K Units)
Table 29. Global Injectable HIV Treatment Sales Market Share Geographic Region (2021-2026)
Table 30. Global Injectable HIV Treatment Revenue by Geographic Region (2021-2026) & ($ millions)
Table 31. Global Injectable HIV Treatment Revenue Market Share by Geographic Region (2021-2026)
Table 32. Global Injectable HIV Treatment Sales by Country/Region (2021-2026) & (K Units)
Table 33. Global Injectable HIV Treatment Sales Market Share by Country/Region (2021-2026)
Table 34. Global Injectable HIV Treatment Revenue by Country/Region (2021-2026) & ($ millions)
Table 35. Global Injectable HIV Treatment Revenue Market Share by Country/Region (2021-2026)
Table 36. Americas Injectable HIV Treatment Sales by Country (2021-2026) & (K Units)
Table 37. Americas Injectable HIV Treatment Sales Market Share by Country (2021-2026)
Table 38. Americas Injectable HIV Treatment Revenue by Country (2021-2026) & ($ millions)
Table 39. Americas Injectable HIV Treatment Sales by Type (2021-2026) & (K Units)
Table 40. Americas Injectable HIV Treatment Sales by Application (2021-2026) & (K Units)
Table 41. APAC Injectable HIV Treatment Sales by Region (2021-2026) & (K Units)
Table 42. APAC Injectable HIV Treatment Sales Market Share by Region (2021-2026)
Table 43. APAC Injectable HIV Treatment Revenue by Region (2021-2026) & ($ millions)
Table 44. APAC Injectable HIV Treatment Sales by Type (2021-2026) & (K Units)
Table 45. APAC Injectable HIV Treatment Sales by Application (2021-2026) & (K Units)
Table 46. Europe Injectable HIV Treatment Sales by Country (2021-2026) & (K Units)
Table 47. Europe Injectable HIV Treatment Revenue by Country (2021-2026) & ($ millions)
Table 48. Europe Injectable HIV Treatment Sales by Type (2021-2026) & (K Units)
Table 49. Europe Injectable HIV Treatment Sales by Application (2021-2026) & (K Units)
Table 50. Middle East & Africa Injectable HIV Treatment Sales by Country (2021-2026) & (K Units)
Table 51. Middle East & Africa Injectable HIV Treatment Revenue Market Share by Country (2021-2026)
Table 52. Middle East & Africa Injectable HIV Treatment Sales by Type (2021-2026) & (K Units)
Table 53. Middle East & Africa Injectable HIV Treatment Sales by Application (2021-2026) & (K Units)
Table 54. Key Market Drivers & Growth Opportunities of Injectable HIV Treatment
Table 55. Key Market Challenges & Risks of Injectable HIV Treatment
Table 56. Key Industry Trends of Injectable HIV Treatment
Table 57. Injectable HIV Treatment Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Injectable HIV Treatment Distributors List
Table 60. Injectable HIV Treatment Customer List
Table 61. Global Injectable HIV Treatment Sales Forecast by Region (2027-2032) & (K Units)
Table 62. Global Injectable HIV Treatment Revenue Forecast by Region (2027-2032) & ($ millions)
Table 63. Americas Injectable HIV Treatment Sales Forecast by Country (2027-2032) & (K Units)
Table 64. Americas Injectable HIV Treatment Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 65. APAC Injectable HIV Treatment Sales Forecast by Region (2027-2032) & (K Units)
Table 66. APAC Injectable HIV Treatment Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 67. Europe Injectable HIV Treatment Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Europe Injectable HIV Treatment Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Middle East & Africa Injectable HIV Treatment Sales Forecast by Country (2027-2032) & (K Units)
Table 70. Middle East & Africa Injectable HIV Treatment Revenue Forecast by Country (2027-2032) & ($ millions)
Table 71. Global Injectable HIV Treatment Sales Forecast by Type (2027-2032) & (K Units)
Table 72. Global Injectable HIV Treatment Revenue Forecast by Type (2027-2032) & ($ millions)
Table 73. Global Injectable HIV Treatment Sales Forecast by Application (2027-2032) & (K Units)
Table 74. Global Injectable HIV Treatment Revenue Forecast by Application (2027-2032) & ($ millions)
Table 75. ViiV Healthcare Basic Information, Injectable HIV Treatment Manufacturing Base, Sales Area and Its Competitors
Table 76. ViiV Healthcare Injectable HIV Treatment Product Portfolios and Specifications
Table 77. ViiV Healthcare Injectable HIV Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 78. ViiV Healthcare Main Business
Table 79. ViiV Healthcare Latest Developments
Table 80. Janssen Pharmaceuticals Basic Information, Injectable HIV Treatment Manufacturing Base, Sales Area and Its Competitors
Table 81. Janssen Pharmaceuticals Injectable HIV Treatment Product Portfolios and Specifications
Table 82. Janssen Pharmaceuticals Injectable HIV Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 83. Janssen Pharmaceuticals Main Business
Table 84. Janssen Pharmaceuticals Latest Developments
Table 85. Gilead Sciences Basic Information, Injectable HIV Treatment Manufacturing Base, Sales Area and Its Competitors
Table 86. Gilead Sciences Injectable HIV Treatment Product Portfolios and Specifications
Table 87. Gilead Sciences Injectable HIV Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 88. Gilead Sciences Main Business
Table 89. Gilead Sciences Latest Developments
Table 90. Theratechnologies Basic Information, Injectable HIV Treatment Manufacturing Base, Sales Area and Its Competitors
Table 91. Theratechnologies Injectable HIV Treatment Product Portfolios and Specifications
Table 92. Theratechnologies Injectable HIV Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 93. Theratechnologies Main Business
Table 94. Theratechnologies Latest Developments
Table 1. Injectable HIV Treatment Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Injectable HIV Treatment Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Cabotegravir
Table 4. Major Players of Rilpivirine
Table 5. Major Players of Lenacapavir
Table 6. Major Players of Ibalizumab
Table 7. Major Players of Other
Table 8. Global Injectable HIV Treatment Sales by Type (2021-2026) & (K Units)
Table 9. Global Injectable HIV Treatment Sales Market Share by Type (2021-2026)
Table 10. Global Injectable HIV Treatment Revenue by Type (2021-2026) & ($ million)
Table 11. Global Injectable HIV Treatment Revenue Market Share by Type (2021-2026)
Table 12. Global Injectable HIV Treatment Sale Price by Type (2021-2026) & (US$/Unit)
Table 13. Global Injectable HIV Treatment Sale by Application (2021-2026) & (K Units)
Table 14. Global Injectable HIV Treatment Sale Market Share by Application (2021-2026)
Table 15. Global Injectable HIV Treatment Revenue by Application (2021-2026) & ($ million)
Table 16. Global Injectable HIV Treatment Revenue Market Share by Application (2021-2026)
Table 17. Global Injectable HIV Treatment Sale Price by Application (2021-2026) & (US$/Unit)
Table 18. Global Injectable HIV Treatment Sales by Company (2021-2026) & (K Units)
Table 19. Global Injectable HIV Treatment Sales Market Share by Company (2021-2026)
Table 20. Global Injectable HIV Treatment Revenue by Company (2021-2026) & ($ millions)
Table 21. Global Injectable HIV Treatment Revenue Market Share by Company (2021-2026)
Table 22. Global Injectable HIV Treatment Sale Price by Company (2021-2026) & (US$/Unit)
Table 23. Key Manufacturers Injectable HIV Treatment Producing Area Distribution and Sales Area
Table 24. Players Injectable HIV Treatment Products Offered
Table 25. Injectable HIV Treatment Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Injectable HIV Treatment Sales by Geographic Region (2021-2026) & (K Units)
Table 29. Global Injectable HIV Treatment Sales Market Share Geographic Region (2021-2026)
Table 30. Global Injectable HIV Treatment Revenue by Geographic Region (2021-2026) & ($ millions)
Table 31. Global Injectable HIV Treatment Revenue Market Share by Geographic Region (2021-2026)
Table 32. Global Injectable HIV Treatment Sales by Country/Region (2021-2026) & (K Units)
Table 33. Global Injectable HIV Treatment Sales Market Share by Country/Region (2021-2026)
Table 34. Global Injectable HIV Treatment Revenue by Country/Region (2021-2026) & ($ millions)
Table 35. Global Injectable HIV Treatment Revenue Market Share by Country/Region (2021-2026)
Table 36. Americas Injectable HIV Treatment Sales by Country (2021-2026) & (K Units)
Table 37. Americas Injectable HIV Treatment Sales Market Share by Country (2021-2026)
Table 38. Americas Injectable HIV Treatment Revenue by Country (2021-2026) & ($ millions)
Table 39. Americas Injectable HIV Treatment Sales by Type (2021-2026) & (K Units)
Table 40. Americas Injectable HIV Treatment Sales by Application (2021-2026) & (K Units)
Table 41. APAC Injectable HIV Treatment Sales by Region (2021-2026) & (K Units)
Table 42. APAC Injectable HIV Treatment Sales Market Share by Region (2021-2026)
Table 43. APAC Injectable HIV Treatment Revenue by Region (2021-2026) & ($ millions)
Table 44. APAC Injectable HIV Treatment Sales by Type (2021-2026) & (K Units)
Table 45. APAC Injectable HIV Treatment Sales by Application (2021-2026) & (K Units)
Table 46. Europe Injectable HIV Treatment Sales by Country (2021-2026) & (K Units)
Table 47. Europe Injectable HIV Treatment Revenue by Country (2021-2026) & ($ millions)
Table 48. Europe Injectable HIV Treatment Sales by Type (2021-2026) & (K Units)
Table 49. Europe Injectable HIV Treatment Sales by Application (2021-2026) & (K Units)
Table 50. Middle East & Africa Injectable HIV Treatment Sales by Country (2021-2026) & (K Units)
Table 51. Middle East & Africa Injectable HIV Treatment Revenue Market Share by Country (2021-2026)
Table 52. Middle East & Africa Injectable HIV Treatment Sales by Type (2021-2026) & (K Units)
Table 53. Middle East & Africa Injectable HIV Treatment Sales by Application (2021-2026) & (K Units)
Table 54. Key Market Drivers & Growth Opportunities of Injectable HIV Treatment
Table 55. Key Market Challenges & Risks of Injectable HIV Treatment
Table 56. Key Industry Trends of Injectable HIV Treatment
Table 57. Injectable HIV Treatment Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Injectable HIV Treatment Distributors List
Table 60. Injectable HIV Treatment Customer List
Table 61. Global Injectable HIV Treatment Sales Forecast by Region (2027-2032) & (K Units)
Table 62. Global Injectable HIV Treatment Revenue Forecast by Region (2027-2032) & ($ millions)
Table 63. Americas Injectable HIV Treatment Sales Forecast by Country (2027-2032) & (K Units)
Table 64. Americas Injectable HIV Treatment Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 65. APAC Injectable HIV Treatment Sales Forecast by Region (2027-2032) & (K Units)
Table 66. APAC Injectable HIV Treatment Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 67. Europe Injectable HIV Treatment Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Europe Injectable HIV Treatment Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Middle East & Africa Injectable HIV Treatment Sales Forecast by Country (2027-2032) & (K Units)
Table 70. Middle East & Africa Injectable HIV Treatment Revenue Forecast by Country (2027-2032) & ($ millions)
Table 71. Global Injectable HIV Treatment Sales Forecast by Type (2027-2032) & (K Units)
Table 72. Global Injectable HIV Treatment Revenue Forecast by Type (2027-2032) & ($ millions)
Table 73. Global Injectable HIV Treatment Sales Forecast by Application (2027-2032) & (K Units)
Table 74. Global Injectable HIV Treatment Revenue Forecast by Application (2027-2032) & ($ millions)
Table 75. ViiV Healthcare Basic Information, Injectable HIV Treatment Manufacturing Base, Sales Area and Its Competitors
Table 76. ViiV Healthcare Injectable HIV Treatment Product Portfolios and Specifications
Table 77. ViiV Healthcare Injectable HIV Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 78. ViiV Healthcare Main Business
Table 79. ViiV Healthcare Latest Developments
Table 80. Janssen Pharmaceuticals Basic Information, Injectable HIV Treatment Manufacturing Base, Sales Area and Its Competitors
Table 81. Janssen Pharmaceuticals Injectable HIV Treatment Product Portfolios and Specifications
Table 82. Janssen Pharmaceuticals Injectable HIV Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 83. Janssen Pharmaceuticals Main Business
Table 84. Janssen Pharmaceuticals Latest Developments
Table 85. Gilead Sciences Basic Information, Injectable HIV Treatment Manufacturing Base, Sales Area and Its Competitors
Table 86. Gilead Sciences Injectable HIV Treatment Product Portfolios and Specifications
Table 87. Gilead Sciences Injectable HIV Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 88. Gilead Sciences Main Business
Table 89. Gilead Sciences Latest Developments
Table 90. Theratechnologies Basic Information, Injectable HIV Treatment Manufacturing Base, Sales Area and Its Competitors
Table 91. Theratechnologies Injectable HIV Treatment Product Portfolios and Specifications
Table 92. Theratechnologies Injectable HIV Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 93. Theratechnologies Main Business
Table 94. Theratechnologies Latest Developments
LIST OF FIGURES
Figure 1. Picture of Injectable HIV Treatment
Figure 2. Injectable HIV Treatment Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Injectable HIV Treatment Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Injectable HIV Treatment Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Injectable HIV Treatment Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Injectable HIV Treatment Sales Market Share by Country/Region (2025)
Figure 10. Injectable HIV Treatment Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Cabotegravir
Figure 12. Product Picture of Rilpivirine
Figure 13. Product Picture of Lenacapavir
Figure 14. Product Picture of Ibalizumab
Figure 15. Product Picture of Other
Figure 16. Global Injectable HIV Treatment Sales Market Share by Type in 2026
Figure 17. Global Injectable HIV Treatment Revenue Market Share by Type (2021-2026)
Figure 18. Injectable HIV Treatment Consumed in Pre-Exposure Prophylaxis
Figure 19. Global Injectable HIV Treatment Market: Pre-Exposure Prophylaxis (2021-2026) & (K Units)
Figure 20. Injectable HIV Treatment Consumed in HIV Treatment
Figure 21. Global Injectable HIV Treatment Market: HIV Treatment (2021-2026) & (K Units)
Figure 22. Global Injectable HIV Treatment Sale Market Share by Application (2025)
Figure 23. Global Injectable HIV Treatment Revenue Market Share by Application in 2026
Figure 24. Injectable HIV Treatment Sales by Company in 2026 (K Units)
Figure 25. Global Injectable HIV Treatment Sales Market Share by Company in 2026
Figure 26. Injectable HIV Treatment Revenue by Company in 2026 ($ millions)
Figure 27. Global Injectable HIV Treatment Revenue Market Share by Company in 2026
Figure 28. Global Injectable HIV Treatment Sales Market Share by Geographic Region (2021-2026)
Figure 29. Global Injectable HIV Treatment Revenue Market Share by Geographic Region in 2026
Figure 30. Americas Injectable HIV Treatment Sales 2021-2026 (K Units)
Figure 31. Americas Injectable HIV Treatment Revenue 2021-2026 ($ millions)
Figure 32. APAC Injectable HIV Treatment Sales 2021-2026 (K Units)
Figure 33. APAC Injectable HIV Treatment Revenue 2021-2026 ($ millions)
Figure 34. Europe Injectable HIV Treatment Sales 2021-2026 (K Units)
Figure 35. Europe Injectable HIV Treatment Revenue 2021-2026 ($ millions)
Figure 36. Middle East & Africa Injectable HIV Treatment Sales 2021-2026 (K Units)
Figure 37. Middle East & Africa Injectable HIV Treatment Revenue 2021-2026 ($ millions)
Figure 38. Americas Injectable HIV Treatment Sales Market Share by Country in 2026
Figure 39. Americas Injectable HIV Treatment Revenue Market Share by Country (2021-2026)
Figure 40. Americas Injectable HIV Treatment Sales Market Share by Type (2021-2026)
Figure 41. Americas Injectable HIV Treatment Sales Market Share by Application (2021-2026)
Figure 42. United States Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 43. Canada Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 44. Mexico Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 45. Brazil Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 46. APAC Injectable HIV Treatment Sales Market Share by Region in 2026
Figure 47. APAC Injectable HIV Treatment Revenue Market Share by Region (2021-2026)
Figure 48. APAC Injectable HIV Treatment Sales Market Share by Type (2021-2026)
Figure 49. APAC Injectable HIV Treatment Sales Market Share by Application (2021-2026)
Figure 50. China Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 51. Japan Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 52. South Korea Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 53. Southeast Asia Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 54. India Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 55. Australia Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 56. China Taiwan Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 57. Europe Injectable HIV Treatment Sales Market Share by Country in 2026
Figure 58. Europe Injectable HIV Treatment Revenue Market Share by Country (2021-2026)
Figure 59. Europe Injectable HIV Treatment Sales Market Share by Type (2021-2026)
Figure 60. Europe Injectable HIV Treatment Sales Market Share by Application (2021-2026)
Figure 61. Germany Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 62. France Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 63. UK Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 64. Italy Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 65. Russia Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 66. Middle East & Africa Injectable HIV Treatment Sales Market Share by Country (2021-2026)
Figure 67. Middle East & Africa Injectable HIV Treatment Sales Market Share by Type (2021-2026)
Figure 68. Middle East & Africa Injectable HIV Treatment Sales Market Share by Application (2021-2026)
Figure 69. Egypt Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 70. South Africa Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 71. Israel Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 72. Turkey Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 73. GCC Countries Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Injectable HIV Treatment in 2026
Figure 75. Manufacturing Process Analysis of Injectable HIV Treatment
Figure 76. Industry Chain Structure of Injectable HIV Treatment
Figure 77. Channels of Distribution
Figure 78. Global Injectable HIV Treatment Sales Market Forecast by Region (2027-2032)
Figure 79. Global Injectable HIV Treatment Revenue Market Share Forecast by Region (2027-2032)
Figure 80. Global Injectable HIV Treatment Sales Market Share Forecast by Type (2027-2032)
Figure 81. Global Injectable HIV Treatment Revenue Market Share Forecast by Type (2027-2032)
Figure 82. Global Injectable HIV Treatment Sales Market Share Forecast by Application (2027-2032)
Figure 83. Global Injectable HIV Treatment Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Injectable HIV Treatment
Figure 2. Injectable HIV Treatment Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Injectable HIV Treatment Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Injectable HIV Treatment Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Injectable HIV Treatment Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Injectable HIV Treatment Sales Market Share by Country/Region (2025)
Figure 10. Injectable HIV Treatment Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Cabotegravir
Figure 12. Product Picture of Rilpivirine
Figure 13. Product Picture of Lenacapavir
Figure 14. Product Picture of Ibalizumab
Figure 15. Product Picture of Other
Figure 16. Global Injectable HIV Treatment Sales Market Share by Type in 2026
Figure 17. Global Injectable HIV Treatment Revenue Market Share by Type (2021-2026)
Figure 18. Injectable HIV Treatment Consumed in Pre-Exposure Prophylaxis
Figure 19. Global Injectable HIV Treatment Market: Pre-Exposure Prophylaxis (2021-2026) & (K Units)
Figure 20. Injectable HIV Treatment Consumed in HIV Treatment
Figure 21. Global Injectable HIV Treatment Market: HIV Treatment (2021-2026) & (K Units)
Figure 22. Global Injectable HIV Treatment Sale Market Share by Application (2025)
Figure 23. Global Injectable HIV Treatment Revenue Market Share by Application in 2026
Figure 24. Injectable HIV Treatment Sales by Company in 2026 (K Units)
Figure 25. Global Injectable HIV Treatment Sales Market Share by Company in 2026
Figure 26. Injectable HIV Treatment Revenue by Company in 2026 ($ millions)
Figure 27. Global Injectable HIV Treatment Revenue Market Share by Company in 2026
Figure 28. Global Injectable HIV Treatment Sales Market Share by Geographic Region (2021-2026)
Figure 29. Global Injectable HIV Treatment Revenue Market Share by Geographic Region in 2026
Figure 30. Americas Injectable HIV Treatment Sales 2021-2026 (K Units)
Figure 31. Americas Injectable HIV Treatment Revenue 2021-2026 ($ millions)
Figure 32. APAC Injectable HIV Treatment Sales 2021-2026 (K Units)
Figure 33. APAC Injectable HIV Treatment Revenue 2021-2026 ($ millions)
Figure 34. Europe Injectable HIV Treatment Sales 2021-2026 (K Units)
Figure 35. Europe Injectable HIV Treatment Revenue 2021-2026 ($ millions)
Figure 36. Middle East & Africa Injectable HIV Treatment Sales 2021-2026 (K Units)
Figure 37. Middle East & Africa Injectable HIV Treatment Revenue 2021-2026 ($ millions)
Figure 38. Americas Injectable HIV Treatment Sales Market Share by Country in 2026
Figure 39. Americas Injectable HIV Treatment Revenue Market Share by Country (2021-2026)
Figure 40. Americas Injectable HIV Treatment Sales Market Share by Type (2021-2026)
Figure 41. Americas Injectable HIV Treatment Sales Market Share by Application (2021-2026)
Figure 42. United States Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 43. Canada Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 44. Mexico Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 45. Brazil Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 46. APAC Injectable HIV Treatment Sales Market Share by Region in 2026
Figure 47. APAC Injectable HIV Treatment Revenue Market Share by Region (2021-2026)
Figure 48. APAC Injectable HIV Treatment Sales Market Share by Type (2021-2026)
Figure 49. APAC Injectable HIV Treatment Sales Market Share by Application (2021-2026)
Figure 50. China Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 51. Japan Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 52. South Korea Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 53. Southeast Asia Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 54. India Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 55. Australia Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 56. China Taiwan Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 57. Europe Injectable HIV Treatment Sales Market Share by Country in 2026
Figure 58. Europe Injectable HIV Treatment Revenue Market Share by Country (2021-2026)
Figure 59. Europe Injectable HIV Treatment Sales Market Share by Type (2021-2026)
Figure 60. Europe Injectable HIV Treatment Sales Market Share by Application (2021-2026)
Figure 61. Germany Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 62. France Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 63. UK Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 64. Italy Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 65. Russia Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 66. Middle East & Africa Injectable HIV Treatment Sales Market Share by Country (2021-2026)
Figure 67. Middle East & Africa Injectable HIV Treatment Sales Market Share by Type (2021-2026)
Figure 68. Middle East & Africa Injectable HIV Treatment Sales Market Share by Application (2021-2026)
Figure 69. Egypt Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 70. South Africa Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 71. Israel Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 72. Turkey Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 73. GCC Countries Injectable HIV Treatment Revenue Growth 2021-2026 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Injectable HIV Treatment in 2026
Figure 75. Manufacturing Process Analysis of Injectable HIV Treatment
Figure 76. Industry Chain Structure of Injectable HIV Treatment
Figure 77. Channels of Distribution
Figure 78. Global Injectable HIV Treatment Sales Market Forecast by Region (2027-2032)
Figure 79. Global Injectable HIV Treatment Revenue Market Share Forecast by Region (2027-2032)
Figure 80. Global Injectable HIV Treatment Sales Market Share Forecast by Type (2027-2032)
Figure 81. Global Injectable HIV Treatment Revenue Market Share Forecast by Type (2027-2032)
Figure 82. Global Injectable HIV Treatment Sales Market Share Forecast by Application (2027-2032)
Figure 83. Global Injectable HIV Treatment Revenue Market Share Forecast by Application (2027-2032)
